Cushing's Disease: Pergolide Compounding Update as FDA Issues Statement on Use of Pergolide Products for Animals

 This statement may also be read on the FDA web site. This statement was posted on March 16, 2012.

On September 7, 2011, the U.S. Food and Drug Administration (FDA or Agency) approved a new animal drug application (NADA) for a product containing pergolide mesylate (NADA 141-331) marketed under the trade name Prascend Tablets for the control of the clinical signs associated with Cushing’s